舒尼替尼对吉非替尼耐药的肺癌细胞的治疗效果及意义

发布时间：2018-02-25 08:35

本文关键词： 肺癌舒尼替尼吉非替尼耐药多药耐药蛋白血管内皮生长因子核转录因子κB　出处：《中国药学杂志》2017年03期 　论文类型：期刊论文

【摘要】：目的探讨舒尼替尼对吉非替尼耐药的肺癌细胞的治疗作用及意义。方法四甲基偶氮唑蓝(MTT)法检测舒尼替尼对28例肺癌患者肿瘤组织提取的吉非替尼耐药细胞的增殖抑制作用;Cell Titer-Glo法检测舒尼替尼给药后,耐药细胞株对吉非替尼的敏感性;流式细胞术方法检测舒尼替尼作用后吉非替尼耐药细胞中Rh-123的含量;Western blot法检测舒尼替尼给药后吉非替尼耐药细胞中多药耐药蛋白(MDR)、核转录因子κB(NF-κB)及血管内皮生长因子(VEGF)蛋白的表达情况。结果舒尼替尼剂量依赖性的抑制吉非替尼耐药细胞的增殖,IC_(50)值为(6.73±1.57)μmol·L~(-1);舒尼替尼可显著增加耐药细胞对吉非替尼的敏感性,降低吉非替尼抑制耐药细胞增殖的IC_(50)值,1和2μmol·L~(-1)舒尼替尼作用耐药细胞株的吉非替尼IC50值分别为(38.64±1.29)与(20.37±1.75)μmol·L~(-1)。1μmol·L~(-1)舒尼替尼给药后可显著增加耐药细胞中Rh-123的含量(P0.05),荧光密度是对照组的2.44倍;2μmol·L~(-1)舒尼替尼给药后耐药细胞中Rh-123的含量与对照组相比具有显著性差异(P0.01),荧光密度是对照组的5.64倍;1和2μmol·L~(-1)的舒尼替尼给药后可显著减少吉非替尼耐药细胞中MDR、NF-κB及VEGF蛋白的表达,并具有剂量依赖性。结论舒尼替尼可逆转吉非替尼耐药,为临床治疗吉非替尼耐药的患者提供理论依据。
[Abstract]:Objective to investigate the therapeutic effect and significance of sulnitinib on gifitinib resistant lung cancer cells. Methods the effect of sulnitinib on tumor cells extracted from 28 patients with lung cancer was detected by MTT assay. The inhibitory effect of sunitinib was detected by cell Titer-Glo method. Sensitivity of drug resistant cell lines to gefitinib; Flow cytometry was used to detect the content of Rh-123 in gefitinib resistant cells after treatment with sunitinib. Western blot assay was used to detect the multidrug resistance protein (MDRN), nuclear transcription factor 魏 B (NF- 魏 NF- 魏 B) and vascular endothelial growth (VEC) in gemfeltinib resistant cells treated with sulnitinib. Results the inhibitory effect of sunitinib on the proliferation of gefitinib resistant cells in a dose-dependent manner was 6.73 卤1.57 渭 mol 路L ~ (-1) mol 路L ~ (-1) 路L ~ (-1), and sunitinib significantly increased the sensitivity of drug resistant cells to gefitinib. The IC50 values of gefitinib on drug resistant cell lines were 38.64 卤1.29) and 20.37 卤1.75 渭 mol 路L ~ (-1) 渭 mol 路L ~ (-1) 路L ~ (-1), respectively, which could significantly increase the content of Rh-123 in drug-resistant cells (P _ (0.05)). Compared with the control group, the content of Rh-123 in the drug resistant cells was significantly different from that in the control group (P 0.01). The fluorescence density was 5.64 times and 2 渭 mol 路L ~ (-1) of the control group. The expression of NF- 魏 B and VEGF protein in drug cells. Conclusion sulnitine can reverse the drug resistance of gefitinib and provide a theoretical basis for the clinical treatment of patients with gefitinib resistance.
【作者单位】：德州市中医院药剂科;
【分类号】：R734.2

【相似文献】